PubMed Health⌕ Search

Biomedical subjects

E Monte

Publications and source records attributed to E Monte.

21 records · Page 2Linked to original sources
PubMed1997

Physiological and biochemical characterization of Trichoderma harzianum, a biological control agent against soilborne fungal plant pathogens.

Monoconidial cultures of 15 isolates of Trichoderma harzianum were characterized on the basis of 82 morphological, physiological, and biochemical features and 99 isoenzyme bands from seven enzyme systems. The results were subjected to numerical analysis which revealed four distinct groups. Representative sequences of the internal transcribed spacer 1 (ITS 1)-ITS 2 region in the ribosomal DNA gene cluster were compared between groups confirming this distribution. The utility of the groupings generated from the morphological, physiological, and biochemical data was assessed by including an additional environmental isolate in the electrophoretic analysis. The in vitro antibiotic activity of the T. harzianum isolates was assayed against 10 isolates of five different soilborne fungal plant pathogens: Aphanomyces cochlioides, Rhizoctonia solani, Phoma betae, Acremonium cucurbitacearum, and Fusarium oxysporum f. sp. radicis lycopersici. Similarities between levels and specificities of biological activity and the numerical characterization groupings are both discussed in relation to antagonist-specific populations in known and potential biocontrol species.

Antibiosis↗
PubMedDate not supplied

Interaction between probucol and cyclosporine in renal transplant patients.

OBJECTIVE: To investigate a possible interaction between probucol and cyclosporine during coadministration. DESIGN: Before/after trial of 15 weeks' duration. SETTING: Clinical pharmacokinetics laboratory of a teritiary care center. PATIENTS: Ten renal transplant patients who were immunosuppressed with cyclosporine therapy for at least six months and who had been receiving probucol for more than eight weeks. METHODS: Patients continued to receive probucol during the first five weeks of the trial (phase A). Probucol then was discontinued until the end of the trial (phase B). Blood samples from each patient were collected at weekly intervals during phase A and again during the last five weeks of phase B. Samples were assayed by fluorescence polarization immunoassay (TDx) to determine trough concentrations of the cyclosporine parent compound in whole blood, and of cyclosporine and metabolites in whole blood and in plasma. Comparison of the data was performed using a paired t-test. RESULTS: An increase in trough concentrations of cyclosporine was observed in phase B (without probucol) with respect to phase A (with probucol). These differences were statistically significant for the cyclosporine parent compound in whole blood (p = 0.02), and for cyclosporine and metabolites in whole blood (p = 0.02) and in plasma (p = 0.001). CONCLUSIONS: When cyclosporine and probucol are coadministered in transplant patients, a close monitoring of cyclosporine concentrations is advised because probucol can induce a decrease in trough concentrations of cyclosporine.

Adult↗